Vamifeport
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Vamifeport
- DrugBank Accession Number
- DB17692
- Background
Vamifeport is being investigated for the treatment of beta-thalassemia.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 408.437
Monoisotopic: 408.171002103 - Chemical Formula
- C21H21FN6O2
- Synonyms
- 2-(2-((2-(1h-benzimidazol-2-yl)ethyl)amino)ethyl)-n-((3-fluoropyridin-2-yl)methyl)-1,3-oxazole-4-carboxamide
- 4-oxazolecarboxamide, 2-(2-((2-(1h-benzimidazol-2-yl)ethyl)amino)ethyl)-n-((3-fluoro-2-pyridinyl)methyl)-
- External IDs
- VIT-2763
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Vamifeport hydrochloride 9DV8VO33JX 2095668-11-2 ZBVCLZMNYXJVMV-UHFFFAOYSA-N
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FUF66UD0KR
- CAS number
- 2095668-10-1
- InChI Key
- KNYVRFXIVWUGBZ-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H21FN6O2/c22-14-4-3-9-24-17(14)12-25-21(29)18-13-30-20(28-18)8-11-23-10-7-19-26-15-5-1-2-6-16(15)27-19/h1-6,9,13,23H,7-8,10-12H2,(H,25,29)(H,26,27)
- IUPAC Name
- 2-(2-{[2-(1H-1,3-benzodiazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide
- SMILES
- FC1=CC=CN=C1CNC(=O)C1=COC(CCNCCC2=NC3=CC=CC=C3N2)=N1
References
- General References
- Not Available
- External Links
- ChemSpider
- 103746305
- ChEMBL
- CHEMBL4596566
- PDBe Ligand
- SZU
- PDB Entries
- 8bzy / 8c03
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Beta-Thalassemia / Non-transfusion Dependent Thalassemia 1 2 Completed Treatment Sickle Cell Disease (SCD) 1 2 Withdrawn Treatment Beta-Thalassemia 1 1 Completed Other Healthy Volunteers (HV) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 1.3 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 108.73 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 107.34 m3·mol-1 Chemaxon Polarizability 43.14 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at April 25, 2023 20:49 / Updated at September 28, 2023 05:47